Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H1 2018

March 2018 | 66 pages | ID: SEE649CA686EN
Global Markets Direct

Abstracts

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H1 2018

SUMMARY

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney.

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 4 respectively.

Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Hormonal Disorders, Metabolic Disorders, Oncology, Central Nervous System, Gastrointestinal, Genetic Disorders, Ophthalmology and Women's Health which include indications Acromegaly, Neuroendocrine Tumors, Diabetic Retinopathy, Pituitary ACTH Hypersecretion (Cushing Disease), Age Related Macular Degeneration, Chronic Pain, Gastric Motility Disorder, Gastrointestinal Tumor, Hypoglycemia, Ileus (Intestinal Obstruction), Medulloblastoma, Meningioma, Neuroblastoma, Neuropathic Pain, Pancreatic Tumor, Pituitary Tumor, Polycystic Kidney Disease, Type 2 Diabetes and Women Infertility.

The latest report Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H1 2018, outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
• The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIM-23627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRL-2903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Neuroendocrine Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones
Featured News & Press Releases
Feb 13, 2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumors (NETs)
Jan 15, 2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018
Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
Sep 21, 2017: JDRF Funds Zucara Therapeutics' Approach to Preventing Hypoglycemia in People with Type 1 Diabetes
Sep 18, 2017: U.S. FDA Approves New Indication for Ipsen’s Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Sep 04, 2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress
Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
Jul 03, 2017: Somatuline Autogel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors
Jun 01, 2017: Ipsen To Present New Data of Lanreotide at ASCO
Mar 09, 2017: Ipsen announces data presentation on lanreotide (Somatuline Autogel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference
Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
Dec 02, 2016: Amryt Pharma provides update on AP-102
Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly
Sep 30, 2016: Ipsen Biopharmaceuticals Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society Symposium
Sep 27, 2016: Ipsen Announces Data Presentations of Lanreotide (Somatuline Autogel) at the European Society for Medical Oncology (ESMO) 2016 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Amryt Pharma plc, H1 2018
Pipeline by Crinetics Pharmaceuticals Inc, H1 2018
Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Pipeline by Ipsen SA, H1 2018
Pipeline by Progenics Pharmaceuticals Inc, H1 2018
Pipeline by Strongbridge Biopharma plc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Zucara Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Zucara Therapeutics Inc